长效广谱中和HIV-1单克隆抗体VRC01LS在暴露新生儿中的安全性、耐受性与药代动力学
本研究在HIV-1暴露非母乳喂养(队列1,n=10)和母乳喂养(队列2,n=11)婴儿中皮下注射长效bNAb VRC01LS(出生后80 mg,队列2在12周加用100 mg),所有婴儿均接受抗逆转录病毒预防。局部反应均为≤2级,剂量1后发生率67%、剂量2后20%;单次给药后24小时平均血浆浓度222.3 µg/mL,12周时为44.0 µg/mL,终末半衰期37-41天。无婴儿感染HIV-1,药代动力学支持进一步研究更高效长效bNAbs作为抗逆转录病毒辅助预防婴儿HIV-1传播。
要点
- VRC01LS皮下给药在HIV-1暴露新生儿中耐受良好,局部反应均为≤2级。
- 单次80 mg剂量后24小时平均血浆浓度222.3 µg/mL,12周时44.0 µg/mL。
核心结论
- VRC01LS在HIV-1暴露新生儿中耐受良好,药代动力学支持进一步研究更高效长效bNAbs作为抗逆转录病毒辅助预防婴儿HIV-1传播。
研究设计与样本
- 扩展半衰期bNAb VRC01LS在HIV-1暴露非母乳喂养婴儿(队列1,n=10)和母乳喂养婴儿(队列2,n=11)中出生后皮下注射80 mg/剂,队列2在12周接受第二剂100 mg,所有婴儿均接受抗逆转录病毒预防。
- VRC01LS水平与先前队列中测定的VRC01水平进行比较。
主要发现
- 局部反应(均为≤2级)在剂量1后发生率为67%,剂量2后为20%。
- 按体重调整剂量(平均28.8 mg/kg)皮下给药后24小时内平均(标准差)血浆浓度为222.3(71.6)µg/mL,第12周(剂量2前)为44.0(11.6)µg/mL。
- 预设目标≥50 µg/mL在第8周和第12周分别达到95%和32%。
- 终末半衰期为37-41天。
关键数值与推荐
- 局部反应均为≤2级。
- 预设目标血浆浓度≥50 µg/mL在第8周达到95%、第12周达到32%。
- 终末半衰期37-41天。
临床怎么用
- VRC01LS皮下给药在HIV-1暴露新生儿中耐受良好,可作为长效bNAbs预防婴儿HIV-1传播的候选方案进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perinatal human immunodeficiency virus type 1 (HIV-1) continues to occur due to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly neutralizing monoclonal antibodies (bNAbs). METHODS: An extended half-life bNAb, VRC01LS, was administered subcutaneously at 80 mg/dose after birth to HIV-1-exposed, nonbreastfed (cohort 1, n = 10) and breastfed (cohort 2, n = 11) infants. Cohort 2 received a second dose (100 mg) at 12 weeks. All received antiretroviral prophylaxis. VRC01LS levels were compared to VRC01 levels determined in a prior cohort. RESULTS: Local reactions (all grade ≤2) occurred in 67% and 20% after dose 1 and dose 2, respectively. The weight-banded dose (mean 28.8 mg/kg) of VRC01LS administered subcutaneously achieved a mean (standard deviation) plasma level of 222.3 (71.6) µg/mL by 24 hours and 44.0 (11.6) µg/mL at week 12, prior to dose 2. The preestablished target of ≥50 µg/mL was attained in 95% and 32% at weeks 8 and 12, respectively. The terminal half-life was 37-41 days. VRC01LS level after 1 dose was significantly greater (P <.002) than after a VRC01 dose (20 mg/kg). No infants acquired HIV-1. CONCLUSIONS: VRC01LS was well tolerated with pharmacokinetics that support further studies of more potent long-acting bNAbs as adjunct treatment with antiretrovirals to prevent infant HIV-1 transmission.
引用
- McFarland EJ, Cunningham CK, Muresan P, et al. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021. PMID: 34009371. doi:10.1093/infdis/jiab229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。